Esomeprazole FDA Approval in Children With GERD
Justin Earp(United States Food and Drug Administration), Christine Garnett(United States Food and Drug Administration), Donna Griebel(United States Food and Drug Administration), Erica L. Wynn(United States Food and Drug Administration), Kerstin Röhss(AstraZeneca (Sweden)), Robert P. Fiorentino(United States Food and Drug Administration), Nitin Mehrotra(Center for Drug Evaluation and Research), Marie Sandström(Uppsala University Hospital), Andrew E. Mulberg, Amy Taylor(United States Food and Drug Administration), Jan‐Stefan Van der Walt(Uppsala University), Kristina E. Peters(United States Food and Drug Administration), Christoffer W. Tornøe(Cleveland Clinic Lerner College of Medicine), Sue Chih Lee(United States Food and Drug Administration)
Cited by 14
Related Papers
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
|New England Journal of Medicine|2023|2.6k
Pharmacokinetics and pharmacodynamics of esomeprazole, the S‐isomer of omeprazole
|Alimentary Pharmacology & Therapeutics|2001|175
Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects
|European Journal of Clinical Pharmacology|2000|140
Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole
|British Journal of Clinical Pharmacology|1998|124
Effect of Esomeprazole 40 mg vs Omeprazole 40 mg on 24-Hour Intragastric pH in Patients with Symptoms of Gastroesophageal Reflux Disease
|Digestive Diseases and Sciences|2002|93